Literature DB >> 18615506

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

Yuhong Zhou1, Haijun Wang, Wenjing Fang, Jorge E Romaguer, Yanxia Zhang, Kay B Delasalle, Larry Kwak, Qing Yi, Xianglin L Du, Michael Wang.   

Abstract

BACKGROUND: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma. To the authors' knowledge, little is known regarding its incidence patterns and associated factors. The purpose of the current study was to examine the incidence of MCL over a period of 13 years and to identify the factors associated with the incidence patterns.
METHODS: Patients diagnosed with MCL between 1992 and 2004 were identified from the Surveillance, Epidemiology, and End Results (SEER) Tumor registries. SEER*Stat statistical software was used for analysis.
RESULTS: Of the 87,166 patients diagnosed with non-Hodgkin's lymphoma during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL. The overall incidence of MCL (per 100,000) was 0.55, which increased with age: 0.07 in patients aged <50 years, 2.97 in patients aged 70 to 79 years, and 2.78 in those aged > or =80 years. The age-adjusted incidence rate increased from 0.27 of 100,000 in 1992 to 0.69 of 100,000 in 2004, and the annual percent change was 5.87% (P < .05). The median age at diagnosis was 68 years. The incidence of MCL was higher in men (0.84 of 100,000) than in women (0.34 of 100,000) (P < .05), and was higher in Caucasians (0.61 of 100,000) than in African Americans (0.32 of 100,000). Late-stage (III-IV) MCL was diagnosed in 74.6% of patients. There were significant geographic variations noted (P < .05).
CONCLUSIONS: The incidence of MCL increased from 1992 to 2004, and was significantly higher in men, in Caucasians, and patients aged > or =50 years. Most patients were diagnosed with late-stage MCL, and there also were considerable geographic variations observed in incidence rate. 2008 American Cancer Society

Entities:  

Mesh:

Year:  2008        PMID: 18615506     DOI: 10.1002/cncr.23608

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  81 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

2.  Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.

Authors:  Jeff D Wang; Samuel G Katz; Elizabeth A Morgan; David T Yang; Xueliang Pan; Mina L Xu
Journal:  Hum Pathol       Date:  2019-08-16       Impact factor: 3.466

Review 3.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Authors:  Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 4.  Mantle cell lymphoma: are current therapies changing the course of disease?

Authors:  Christian Geisler
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

5.  Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Authors:  Stephen M Ansell; Hui Tang; Paul J Kurtin; Patricia A Koenig; David J Inwards; Keith Shah; Steven C Ziesmer; Andrew L Feldman; Radha Rao; Mamta Gupta; Charles Erlichman; Thomas E Witzig
Journal:  Lancet Oncol       Date:  2011-04       Impact factor: 41.316

6.  Mantle cell lymphoma of the oral cavity with multiple foci: a case report and review of the literature.

Authors:  K Rajkumar; Ramesh Rao; Naveen Chawla; T K Bandyopadhyay; Ramen Sinha
Journal:  J Maxillofac Oral Surg       Date:  2012-05-16

7.  Gastrointestinal Mantle Cell Lymphoma with Varied Findings.

Authors:  Atsushi Goto; Jun Nishikawa; Shunsuke Ito; Eizaburou Hideura; Tomohiro Shirasawa; Koichi Hamabe; Shinichi Hashimoto; Takeshi Okamoto; Isao Sakaida
Journal:  J Gastrointest Cancer       Date:  2020-03

8.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Authors:  Jimmy Lee; Liang Leo Zhang; Wenjun Wu; Hui Guo; Yan Li; Madina Sukhanova; Girish Venkataraman; Shengjian Huang; Hui Zhang; Mir Alikhan; Pin Lu; Ailin Guo; Natalie Galanina; Jorge Andrade; Michael L Wang; Y Lynn Wang
Journal:  Blood Adv       Date:  2018-08-28

Review 9.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

Review 10.  Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.

Authors:  Kelly Guggisberg; Richard C K Jordan
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.